New macrolide, lincosaminide and streptogramin B antibiotics.
BACKGROUND
New antibiotics are needed to overcome microbial resistance and to improve on the therapeutic index and clinical effectiveness of existing agents.


METHODS
This review covers the journal and patent literature published from about the mid-2000s to 2010 to provide an overview of the large diversity of new chemical entities in the macrolide, lincosaminide and streptogramin B (MLS(B)) class.


RESULTS
The review identifies areas of the greatest effort and recent results in pursuing structure-activity relationships among MLS(B) antibiotics and highlights preclinical and clinical candidates that have arisen from these diverse discovery programs.


CONCLUSIONS
Research on the MLS(B) class appears promising for the eventual registration and commercialization of several new antibiotics that improve the clinical effectiveness of existing agents and combat antibiotic-resistant pathogens.
Kirst
Herbert A
HA
Eli Lilly and Company, 7840 West 88th Street, Indianapolis, IN 46278, USA. herbertkirst1@comcast.net
D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D055808:Drug Discovery; D004352:Drug Resistance, Microbial / Q000187:drug effects; D006801:Humans; D055231:Lincosamides / Q000494:pharmacology / Q000627:therapeutic use*; D018942:Macrolides / Q000494:pharmacology / Q000627:therapeutic use*; D025381:Streptogramin B / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D055231:Lincosamides; D018942:Macrolides; D025381:Streptogramin B